meta
|
COVID-19
Dynamic meta-analysis of evidences about drug efficacy and safety
adjuvant therapies
anti-inflammatoty and immuno-therapy
antiviral and associated therapy
control
honey
miscellaneous
5-alpha-reductase inhibitors
acetylcysteine
alpha lipoic acid
aviptadil
bevacizumab
bismuth
BLD-2660 (calpain inhibitor)
calcium channel blocker
camostat mesilate
continuous positive airway pressure (CPAP)
cytokine adsorption
diammonium glycyrrhizinate
dipyridamol
DPP-4 inhibitor
enoxaparin
famotidine
kinin-kallikrein inhibitors
levamisole
metformin
natural killer (NK) cells
nicotin
nitric oxide (gas Inhalation or releasing solution)
ozonated autohemotherapy
pamrevlumab
povidone-iodine
proton pump inhibitors (PPI)
proxalutamide
PUL-042 inhalation solution
radiotherapy
selinexor
statins
stem cells
tradipitant
tranilast
zinc
zinc plus hydroxychloroquine
vaccines
COVID-19
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 prophylaxis
infections other than COVID-19
preventing respiratory virus transmission
Meta-analysis results for all treatments
Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE).
method
Treament
Trials
Summary
Endpoints
death or transfer to ICU
deaths
clinical deterioration
conversion to SARS-CoV- 2–positive status via NP swab
death or ventilation
laboratory-confirmed Covid-19
new illness compatible with Covid-19
PCR-negative conversion
ventilation
ICU admission
superinfection
core analysis (OBS if no RCT)
RCTs only
all (RCT+OBS)
clinical deterioration
clinical improvement
deaths
PCR-negative conversion
proton pump inhibitors (PPI)
6
OBS
2.71
[1.17; 6.30], 1 study, I2=0%
statistically significant harm
-
OBS
1.76
[0.62; 4.99], 3 studies, I2=81%
inconclusive result
-
alpha lipoic acid
1
-
-
0.17
[0.02; 1.44], 1 RCT, I2=0%
inconclusive result
-
famotidine
1
-
-
OBS
1.64
[1.14; 2.36], 1 study, I2=0%
statistically significant harm
-
5-alpha-reductase inhibitors
0
-
-
-
-
acetylcysteine
0
-
-
-
-
aviptadil
0
-
-
-
-
bevacizumab
0
-
-
-
-
bismuth
0
-
-
-
-
BLD-2660 (calpain inhibitor)
0
-
-
-
-
calcium channel blocker
0
-
-
-
-
camostat mesilate
0
-
-
-
-
continuous positive airway pressure (CPAP)
0
-
-
-
-
cytokine adsorption
0
-
-
-
-
diammonium glycyrrhizinate
0
-
-
-
-
dipyridamol
0
-
-
-
-
DPP-4 inhibitor
0
-
-
-
-
enoxaparin
0
-
-
-
-
kinin-kallikrein inhibitors
0
-
-
-
-
levamisole
0
-
-
-
-
metformin
0
-
-
-
-
natural killer (NK) cells
0
-
-
-
-
nicotin
0
-
-
-
-
nitric oxide (gas Inhalation or releasing solution)
0
-
-
-
-
ozonated autohemotherapy
0
-
-
-
-
pamrevlumab
0
-
-
-
-
povidone-iodine
0
-
-
-
-
proxalutamide
0
-
-
-
-
PUL-042 inhalation solution
0
-
-
-
-
radiotherapy
0
-
-
-
-
selinexor
0
-
-
-
-
statins
0
-
-
-
-
stem cells
0
-
-
-
-
tradipitant
0
-
-
-
-
tranilast
0
-
-
-
-
zinc
0
-
-
-
-